Derry Philip, Derry Sheena, Moore R Andrew, McQuay Henry J
Pain Research, University of Oxford, Nuffield Department of Anaesthetics, West Wing (Level 6), John Radcliffe Hospital, Oxford, Oxfordshire, UK, OX3 9DU.
Cochrane Database Syst Rev. 2009 Apr 15(2):CD004768. doi: 10.1002/14651858.CD004768.pub2.
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID), available as a potassium salt (immediate-release) or sodium salt (delayed-release). This review updates an earlier review published in The Cochrane Database of Systematic Reviews (Issue 2, 2004) on 'Single dose oral diclofenac for postoperative pain'.
To assess single dose oral diclofenac for the treatment of acute postoperative pain.
Cochrane CENTRAL, MEDLINE, EMBASE, Biological Abstracts, the Oxford Pain Relief Database, and reference lists of articles were searched; last search December 2008.
Randomised, double-blind, placebo-controlled clinical trials of single dose, oral diclofenac (sodium or potassium) for acute postoperative pain in adults.
Two review authors independently assessed studies for inclusion and quality, and extracted data. The area under the pain relief versus time curve was used to derive the proportion of participants with at least 50% pain relief over 4 to 6 hours, using validated equations. Relative benefit (risk) and number needed to treat to benefit (NNT) were calculated. Information on adverse events, time to remedication, and participants needing additional analgesia was also collected.
Fifteen studies (eight additional studies) with 1512 participants more than doubled the information available at each dose. Overall 50% to 60% of participants experienced at least 50% pain relief over 4 to 6 hours at any dose with diclofenac, compared to 10 to 20% with placebo, giving NNTs of about 2.5 for doses of 25 mg to 100 mg (similar to earlier review); no dose response was demonstrated. At 50 mg and 100 mg, NNTs for diclofenac potassium (2.1 (1.8 to 2.4) and 1.9 (1.7 to 2.2)) were significantly lower (better) than for diclofenac sodium (6.7 (4.2 to 17) and 4.5 (3.2 to 7.7)). The median time to use of rescue medication was 2 hours for placebo, 4.3 hours for diclofenac 50 mg and 4.9 hours for diclofenac 100 mg. Adverse events were reported at a similar rate to placebo, with no serious events.
AUTHORS' CONCLUSIONS: Oral diclofenac is an effective single-dose treatment for moderate to severe postoperative pain. Significantly more participants experienced at least 50% pain relief over 4 to 6 hours with diclofenac potassium than with diclofenac sodium. There was no significant difference between diclofenac and placebo in the incidence of adverse events.
双氯芬酸是一种非甾体抗炎药(NSAID),有钾盐(速释)或钠盐(缓释)两种剂型。本综述更新了《Cochrane系统评价数据库》(2004年第2期)中发表的关于“单剂量口服双氯芬酸用于术后疼痛”的早期综述。
评估单剂量口服双氯芬酸治疗急性术后疼痛的效果。
检索了Cochrane中心对照试验注册库、MEDLINE、EMBASE、生物学文摘数据库、牛津疼痛缓解数据库以及文章的参考文献列表;最近一次检索时间为2008年12月。
关于单剂量口服双氯芬酸(钠盐或钾盐)用于成人急性术后疼痛的随机、双盲、安慰剂对照临床试验。
两名综述作者独立评估研究是否纳入及质量,并提取数据。使用经过验证的公式,通过疼痛缓解与时间曲线下面积来计算在4至6小时内疼痛缓解至少50%的参与者比例。计算相对获益(风险)和需治疗获益人数(NNT)。还收集了不良事件、补救用药时间以及需要额外镇痛的参与者的信息。
15项研究(新增8项研究)共1512名参与者,使每种剂量下可获得的信息增加了一倍多。总体而言,使用双氯芬酸的任何剂量时,50%至60%的参与者在4至6小时内疼痛缓解至少50%,而安慰剂组为10%至20%,25毫克至100毫克剂量的NNT约为2.5(与早期综述相似);未显示出剂量反应。50毫克和100毫克时,双氯芬酸钾的NNT(分别为2.1(1.8至2.4)和1.9(1.7至2.2))显著低于双氯芬酸钠(分别为6.7(4.2至17)和4.5(3.2至7.7))。安慰剂组使用补救药物的中位时间为2小时,双氯芬酸50毫克组为4.3小时,双氯芬酸100毫克组为4.9小时。不良事件报告率与安慰剂相似,无严重事件。
口服双氯芬酸是治疗中度至重度术后疼痛的有效单剂量疗法。与双氯芬酸钠相比,双氯芬酸钾使更多参与者在4至6小时内疼痛缓解至少50%。双氯芬酸与安慰剂在不良事件发生率上无显著差异。